Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Tolerability of CKD-386(2) vs Co-administration of D013, D326, and D337
NCT04987970Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Sep 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ezetimibe + rosuvastatin + telmisartan in hypertension (HTN) and dyslipidemia (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve from time 0 to last measurable concentration at 72 hours and Maximum Plasma Concentration at 72 hours. Started Sep 2021; status: completed.
02
Drugs
ezetimibe + rosuvastatin + telmisartan
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT04987970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04987970.